Condition: Metastatic Nasopharyngeal Carcinoma · Recurrent Nasopharyngeal Carcinoma · Stage IV Nasopharyngeal Carcinoma AJCC v8 · Sponsor: National Cancer Institute (NCI)
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells growing or spreading longer than the usual approach in patients with recurrent or metastatic nasopharyng…
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Kaiser Permanente Dublin | Dublin, California, United States | Recruiting |
| Kaiser Permanente-Fremont | Fremont, California, United States | Recruiting |
| Kaiser Permanente Fresno Orchard Plaza | Fresno, California, United States | Recruiting |
| Kaiser Permanente-Fresno | Fresno, California, United States | Recruiting |
| Keck Medicine of USC Koreatown | Los Angeles, California, United States | Recruiting |
| Los Angeles General Medical Center | Los Angeles, California, United States | Recruiting |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Kaiser Permanente- Modesto MOB II | Modesto, California, United States | Recruiting |
| Kaiser Permanente-Modesto | Modesto, California, United States | Recruiting |
| USC Norris Oncology/Hematology-Newport Beach | Newport Beach, California, United States | Recruiting |
| Kaiser Permanente-Oakland | Oakland, California, United States | Recruiting |
| Stanford Cancer Institute Palo Alto | Palo Alto, California, United States | Recruiting |
+ 76 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06029270